AstraZeneca Investor Conference Presentation Deck

AstraZeneca positioned to lead in CVRM AstraZeneca to acquire CinCor Pharma to strengthen cardiorenal pipeline Enhancing our position in CVRM Developing and delivering innovative, life-changing medicines and solutions for the millions of people affected by the complex spectrum of CVRM diseases Dyslipidaemia /Thrombosis ↓ Andexxa AZD0870 y Heart failure Farxiga mitiperstat balcinrenone G Chronic kidney disease ↓ Farxiga mitiperstat balcinrenone zibotentan Transthyretin amyloidosis ↓ eplontersen Metabolism ↓ zibotentan Early pipeline Hypertension ↓ baxdrostat CINCOR baxdrostat CINCOR Improving treatment and outcomes for patients; building on Farxiga's success 9 BP = blood pressure; ASIS = aldosterone synthase inhibitors; MRAs = mineralocorticoid receptor antagonists. Collaboration partner: Ionis (eplontersen). The clinical burden of treatment resistant hypertension Hypertension, a silent killer: systolic blood pressure above 130/80 mm Hg 7 million patients in the US are on three or more anti- hypertensive medicines and are still not at BP goal - treatment resistant Current standard of care: ASIS and MRAS (spironolactone) target the aldosterone pathway to lower BP MRAS → undesirable androgenic side effects e.g., gynecomastia

View entire presentation